Works matching IS 21534888 AND DT 2022 AND VI 13 AND IP 2
Results: 24
Study Finds 1 in 6 Patients with Cancer Experience "Long-Haul" COVID-19.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 22
- By:
- Publication type:
- Article
The International Cholangiocarcinoma Research Network Program Initiatives.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 21
- Publication type:
- Article
Elacestrant Yields Positive Outcomes in Patients with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 20
- By:
- Publication type:
- Article
Analysis of Insurance Claims Reveals Upward Trend in the Use of Trastuzumab Biosimilars.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 19
- By:
- Publication type:
- Article
Survey of Oncologists Identifies Several Misconceptions Regarding Biosimilars.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 18
- By:
- Publication type:
- Article
Updated Results from KEYNOTE-564 Trial Confirm Benefit of Adjuvant Pembrolizumab in Patients with Renal-Cell Carcinoma at High Risk for Recurrence.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 17
- By:
- Publication type:
- Article
Neoadjuvant Checkpoint Inhibitor plus TKI for Localized Renal-Cell Carcinoma: Encouraging Disease-Free Survival.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 16
- By:
- Publication type:
- Article
Neoadjuvant Enfortumab Vedotin Appears Promising in Patients with Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 15
- By:
- Publication type:
- Article
Opdivo plus Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 14
- Publication type:
- Article
AK104 plus Chemotherapy Shows Promise in Patients with Advanced Gastric Cancers.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 13
- By:
- Publication type:
- Article
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 12
- Publication type:
- Article
Trastuzumab Deruxtecan Shows Survival Benefit in HER2-Positive Advanced Gastric Cancers.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 12
- By:
- Publication type:
- Article
Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 11
- Publication type:
- Article
Pembrolizumab Added to Best Supportive Care Extends Survival in Advanced HCC.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 11
- By:
- Publication type:
- Article
Kimmtrak, a Bispecific CD3 T-Cell Engager, First FDA-Approved Drug for Unresectable or Metastatic Uveal Melanoma.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 10
- Publication type:
- Article
FDA Approves Vonjo for Treatment of Patients with Myelofibrosis and Thrombocytopenia.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 9
- Publication type:
- Article
Time-Limited Venetoclax-Based Regimens Show Efficacy in Fit Patients with CLL.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 9
- By:
- Publication type:
- Article
Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 8
- Publication type:
- Article
Isatuximab plus RVd Combination Achieves High Rates of No MRD in Patients with Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 8
- By:
- Publication type:
- Article
Community-Based Providers Focus on Optimal Delivery of Care Despite Ongoing Challenges.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 6
- By:
- Publication type:
- Article
Polatuzumab Vedotin plus R-CHP Improves Progression-Free Survival in Newly Diagnosed DLBCL.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 1
- By:
- Publication type:
- Article
Exploring the Future of Genetic Therapies and Value-Based Care in Oncology.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 1
- By:
- Publication type:
- Article
Novel Vaccine plus Chemotherapy Shows Promise in the Treatment of Metastatic Pancreatic Cancer.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 1
- By:
- Publication type:
- Article
Continuous Enzalutamide Reduces Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2022, v. 13, n. 2, p. 1
- By:
- Publication type:
- Article